| ABSTRACT Objective:To evaluate the effectiveness and safety of capecitabine or fluorouracil plus oxaliplatin or cisplatin in the treatment of metastasis gastric cancer. Methods: The six databases as follows: Cochrane Library, PubMed, Embase, CNKI, VIP and WanFang, were retrieved by computer. Randomized controlled trials (RCT) in the treatment of metastatis gastric cancer were included for quality assessment and Meta analysis was performed by using RevMan 5.2 sofetware. Results:A total of 22 RCTs involving 1 601 participants were included. The results showed that capecitabine based regiment had an overall advantage over FU based regiment in terms of overall response rate [RR=1.28, 95%CI（1.15,1.42）, P＜0.001], complete response rate[RR=1.58, 95%CI（1.09,2.30）, P=0.02], partial response rate[RR=1.23, 95%CI（1.09,1.39）, P＜0.001] and disease control rate [RR=1.12, 95%CI（1.06,1.20）, P＜0.001]. For the safety evaluation, the incidence of hand foot syndrome was higher in capecitabine based regiment than FU based regiment, but the incidence of nausea and vomiting, stomatitis and leukopenia were lower in capecitabine based regiment than FU based regiment. The adverse reactions such as diarrhea, neuropathy, dysfunction of liver, anemia and thrombocytopenia did not exhibit any significant differences between the two regiments(P>0.05).Conclusion: Capecitabine plus oxaliplatin or cisplatin has better effectiveness and safety than FU plus oxaliplatin or cisplatin in the treatment of metastasis gastric cancer. The conclusion still needs large sample and multicenter RCT with high quality confirmed. |
